EICHORCondition: Breast Cancer · Sponsor: Centro di Riferimento Oncologico - Aviano
Interested? Contact the study team ↓
Accurate assessment of axillary lymph nodes in patients with breast cancer is essential for prognosis and treatment planning. Staging and surgical management have evolved from axillary lymph node dissection to sentinel lymph node biopsy to minimize morbidity. However, sentinel lymph node biopsy has non-negligible morbidity, and more than 70% of biopsies are negative, calling into question its routine use. Magnetic resonance imaging (MRI) can be used to detect and stage lymph node metastases in situ, but its sensitivity and specificity are moderate to poor. Few studies have employed artificial intelligence to detect lymph node metastases on MRI images, and none have used an integrative multidata approach (IMA), defined as modeling the combination of clinical and laboratory data with multiparametric MRI. The primary objective of this retrospective observational study is to improve the accuracy of detecting lymph node involvement in breast cancer using IMA. The secondary objective is to allow longitudinal monitoring of the effects of neoadjuvant therapy on lymph node involvement
This description comes directly from the study's public registry record.
Fabio Del Ben, PhD · 0434659101 · fabio.delben@cro.it
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Patients diagnosed with breast cancer who underwent MRI and biopsy or surgery of axillary lymph nodes as part of their diagnosis and treatment * Patients of all genders, ages, and stage I-III of breast cancer * Patients who underwent neoadjuvant therapy and have longitudinal imaging data available for analysis (for secondary outcome analysis) Exclusion Criteria: * Patients whose MRI images were of insufficient quality for analysis * Patients who had a previous history of breast cancer * Patients with a history of axillary surgery or lymph node dissection prior to the current diagnosis of breast cancer * Patients who received neoadjuvant therapy at another institution
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Landeskrankenhaus Villach | Villach, Austria | Recruiting |
| KI4LIFE, Fraunhofer Austria Research | Austria, Austria, Italy | Recruiting |
| Klinikum Klagenfurt am Wörthersee Klagenfurt am Wörthersee | Villach, Austria, Italy | Recruiting |
| Centro di Riferimento Oncologico | Aviano, Pordenone, Italy | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06738459